@ year event-free survival was @ % ( @ % CI @-@ ) in patients in the trastuzumab group and @ % ( @-@ ) in those in the chemotherapy group ; the unadjusted hazard ratio ( HR ) for event-free survival between the two randomised HER@-positive treatment groups was @ ( @ % CI @-@ @ ; two-sided log-rank p = @ ) .